Skip to main content
Clinical Trials/NL-OMON46099
NL-OMON46099
Not Yet Recruiting
Phase 2

Improving treatment of right ventricular failure in pulmonary hypertension patients. - Improving treatment of RVF in PH patients.

Vrije Universiteit Medisch Centrum0 sites20 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
High pulmonary blood pressure
Sponsor
Vrije Universiteit Medisch Centrum
Enrollment
20
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • Patients should be diagnosed with pre\-capillary pulmonary hypertension either PAH or CTEPH, have clinical signs of decompensated right heart failure, and needing hospital \- or ICU admission for IV diuretics.
  • PAH (group 1 and 1\*) or CTEPH (group 2\), diagnosed according ESC/ERS guidelines;
  • o Mean Pulmonary Artery Pressure (mPAP) \>\= 25 mmHg
  • o Pulmonary Arterial Wedge Pressure (PCWP) \<15 mmHg
  • o Other possible causes of PH are excluded
  • 18\-70 years old
  • Increased body weight despite increased dose diuretics in past month
  • Clinical signs of decompensation: ankle edema and/or ascites
  • eGFR; 30 ml/min/1\.73m2

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • Pulmonary hypertension due to connective tissue disease, and PH due to left heart disease (group 2\).
  • Hypoxia defined as SaO2 \<\=80% and/or \<\= 90% with oxygen suppletion.
  • Pregnancy, lactation
  • Anuria (urine production \<50 ml/day)
  • Known intolerance of loop diuretics or terlipressin
  • Recent diagnosis (\<1 month ago) of acute pulmonary embolism
  • Underlying infectious disorder/ bacteremia
  • Known history of occlusive arterial disease (e.g. coronary artery disease) and/or peripheral artery disease, exception: pulmonary embolism
  • Type 1 and type 2 diabetes mellitus

Outcomes

Primary Outcomes

Not specified

Similar Trials